Abstract
<p class="Abstract">Extracellular pigment from the forest soil <em>Streptomyces</em> sp SFA5 was produced by submerged fermentation using yeast extract malt extract broth. Crude pigment from the medium was extracted using ethyl acetate. Antitubercular activity of the pigment was tested against <em>M. tuberculosis</em> H37Rv by microplate alamar blue assay and luciferase reporter phage assay. The pigment was also tested for inhibitory activity against <em>M. tuberculosis</em> lysine aminotransferase by colorimetric method. In both microplate alamar blue and luciferase reporter phage assay, the crude pigment showed activity against <em>M. tuberculosis</em> H37Rv at 125 and 250 µg/mL concentration, respectively. The <em>M. tuberculosis</em> lysine aminotransferase was inhibited at the IC<sub>50</sub> value of 4.5 µg/mL concentration.</p><p> </p>
Highlights
The incidence of emerging infectious diseases in humans has increased within the recent past or threatens to increase in the near future
In microplate alamar blue assay, the growth of M. tuberculosis H37Rv was inhibited at 125 μg/mL concentration
In luciferase reporter phage assay, the crude pigment showed 60 and 74% reduction in relative light unit (RLU) at 250 and 500 μg/mL concentration, respectively. Results of both the method showed that the yellow pigment produced by Streptomyces sp SFA5 was active against M. tuberculosis H37Rv
Summary
The incidence of emerging infectious diseases in humans has increased within the recent past or threatens to increase in the near future. Mycobacterium tuberculosis still remains a deadly pathogen two decades after the announcement of tuberculosis as a global health emergency by the World Health Organization. In 2013, an estimated 9.0 million people developed TB and 1.5 million died from the disease, 360,000 of whom were HIV-positive (WHO report, 2014). In last few years new drug combinations have shown promising potential to significantly shorten tuberculosis treatment times. There are very few new chemical entities being developed to treat this global threat (Riccardi and Pasca, 2014). There is a dire need for new chemical entities to develop as potential antitubercular molecules
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.